Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

Protagonist Therapeutics (PTGX) is gearing up to report top-line results from its phase 3 VERIFY study using its subcutaneous injectable Hepcidin Mimetic rusfertide [PTG-300] for the treatment of ...

Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...